Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a synthetic corticosteroid presented as a nasal spray for intranasal administration. It is indicated for the treatment of allergic rhinitis and for reducing nasal polyp size, providing anti‑inflammatory relief in the nasal mucosa of adults and children.

GNH USA supplies Nasonex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on regulatory compliance and reliable logistics.

Nasonex (mometasone furoate) is a nasal corticosteroid that reduces inflammation in the upper airway.

Allergic rhinitis (perennial): reduces nasal congestion, sneezing and itching. Seasonal allergic rhinitis: controls seasonal symptom flare‑ups. Nasal polyps: decreases polyp size and improves nasal airflow.

Nasonex may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleeds) - Throat irritation - Cough - Altered taste or smell

Serious or Rare Side Effects: - Nasal septal perforation - Severe or persistent epistaxis - Adrenal suppression - Vision changes such as cataracts or glaucoma - Opportunistic fungal infection of the nasal passages - Anaphylaxis or severe allergic reaction

Before using Nasonex, consider the following precautions.

Pregnancy: consult a healthcare professional to weigh potential risks and benefits. Breastfeeding: discuss possible effects with a physician before use. Pediatric use: follow pediatric dosing guidance and monitor response. Concurrent intranasal steroids: avoid unless directed by a prescriber. Monitor for signs of adrenal insufficiency, especially with prolonged high‑dose therapy. Store at room temperature: keep in the original container, protect from moisture and heat.

Nasonex can interact with other medicines; review the following categories.

Major Interactions (Avoid): - Systemic corticosteroids: may increase risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise local mometasone exposure. - Live vaccines: potential reduction in vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antifungal azoles: may modestly increase mometasone levels. - Ritonavir or other protease inhibitors: possible interaction affecting metabolism. - Other intranasal medications: may alter absorption or local irritation.